Key statistics
On Tuesday, Amarin Corporation PLC (AMRN:NAQ) closed at 14.35, -31.34% below its 52-week high of 20.90, set on Oct 24, 2025.
52-week range
| Open | 13.72 |
|---|---|
| High | 14.51 |
| Low | 13.66 |
| Bid | 13.67 |
| Offer | 15.65 |
| Previous close | 13.93 |
| Average volume | 102.49k |
|---|---|
| Shares outstanding | 20.79m |
| Free float | 20.72m |
| P/E (TTM) | -- |
| Market cap | 289.64m USD |
| EPS (TTM) | -76.48 USD |
Data delayed at least 15 minutes, as of Mar 03 2026 21:00 GMT.
More ▼
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology
- Amarin Reports Fourth Quarter and Full Year 2025 Financial Results
- This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease
- Amarin to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 25, 2026
- Amarin Applauds Breakthroughs In Therapies For Patients With Elevated Triglycerides; Company’s VASCEPA®/VAZKEPA® (Icosapent Ethyl) Franchise Well Positioned To Benefit Globally From Broadened Category Commercialization
- Amarin Announces Preliminary 2025 Financial Highlights and Operational Accomplishments, Including Achieving Positive Cash Flow; Company Well Positioned to Capture Global Growth Opportunities
- New REDUCE-IT® Aspirin Analysis Presented at AHA Scientific Sessions 2025 Reinforces VASCEPA®/VAZKEPA® (Icosapent Ethyl) Reduced Cardiovascular Events in High-Risk Patients
- Amarin To Present New Analyses Affirming Robustness of Data from REDUCE-IT and Additional Mechanisms of Action of Eicosapentaenoic Acid (EPA) at American Heart Association (AHA) Scientific Sessions 2025
- Amarin Reports Third Quarter 2025 Financial Results
- Amarin Issues Statement Supporting FDA’s Action to Revise Labeling for Fenofibrate Drugs Reinforcing a Lack of Cardiovascular Benefit
More ▼
